RT Journal Article
SR Electronic
T1 COVID-19 Mid-term Impact on Hepatocellular Carcinoma in Patients With Hepatitis C Chronic Infection
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 3377
OP 3383
DO 10.21873/invivo.12636
VO 35
IS 6
A1 GULER-MARGARITIS, SILVIU
A1 MERCAN-STANCIU, ADRIANA
A1 TOMA, LETITIA
A1 RUSIE, DANIEL
A1 ISAC, TEODORA
A1 DODOT, MIHAI
A1 ZGURA, ANCA
A1 BACALBASA, NICOLAE
A1 HAINEALA, BOGDAN
A1 BADIU, DUMITRU CRISTINEL
A1 SERBAN, DRAGOS
A1 ILIESCU, ELENA LAURA
YR 2021
UL http://iv.iiarjournals.org/content/35/6/3377.abstract
AB Background/Aim: Liver injury has been frequently reported in association with SARS-CoV-2 infection, but data are still lacking regarding the impact of pre-existing liver damage and neoplasia on SARS-CoV-2 infection outcome and vice-versa. This study aimed to assess the effects of SARS-CoV-2 infection on hepatocellular carcinoma (HCC) in chronic hepatitis C virus (HCV) infected patients, both in therapeutic-naïve and patients treated with direct acting antivirals. Patients and Methods: We conducted a retrospective cohort study on 21 patients with a personal history of HCV infection, that have been diagnosed with different forms of HCC and who were subsequently infected with SARS-CoV-2. Patients were monitored by liver function tests, tumoral markers, blood cell count, and coagulation profile periodically. Results: Solitary HCC nodules were predominant among the subjects who achieved sustained virologic response, while multinodular and infiltrative patterns were mostly prevalent among the treatment-naïve group. Most patients had mild and moderate COVID-19 infections. Conclusion: Within the current global pandemic crisis, cancer patients are highly vulnerable and in need of constant monitoring. Among patients with HCC, the ones with cured HCV infection may be at a lower risk of fatality than those with active HCV infection, when diagnosed with SARS-CoV-2 infection.